Загрузка...

Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial

BACKGROUND: The approval of extended release injectable naltrexone (XR-NTX; Vivitrol®) has introduced a new option for treating opioid addiction, but studies are needed to identify its place within the spectrum of available therapies. The absence of physiological opioid dependence is a necessary and...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Mannelli, Paolo, Wu, Li-Tzy, Peindl, Kathleen S., Swartz, Marvin S., Woody, George E.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017322/
https://ncbi.nlm.nih.gov/pubmed/24602363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drugalcdep.2014.02.002
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!